Page last updated: 2024-12-06

iprazochrome

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Iprazochrome is a synthetic pyrazolone derivative that exhibits vasodilatory and anti-inflammatory properties. Its mechanism of action involves inhibiting the production of thromboxane A2, a potent vasoconstrictor and platelet aggregator. Iprazochrome is primarily investigated for its potential therapeutic applications in conditions related to peripheral vascular disease, such as intermittent claudication and Raynaud's phenomenon. Research has explored its effects on blood flow, vascular tone, and inflammatory processes in these conditions. The compound's ability to modulate platelet aggregation and its anti-inflammatory properties are also of interest in the context of cardiovascular disease and other inflammatory disorders. However, clinical studies on iprazochrome have yielded mixed results, with some suggesting potential benefits while others indicating limited efficacy or safety concerns. Ongoing research continues to evaluate its therapeutic potential and optimize its use.'

Cross-References

ID SourceID
PubMed CID65594
CHEMBL ID4297107
CHEBI ID135088
SCHEMBL ID231514
SCHEMBL ID231513
SCHEMBL ID10736494
MeSH IDM0054699

Synonyms (46)

Synonym
1-isopropyl-3-hydroxy-5-semicarbazone-6-oxo-2,3,5,6-tetrahydroindole
iprazochrome [inn]
nsc 10065
hydrazinecarboxamide, 2-(1,2,3,6-tetrahydro-3-hydroxy-1-(1-methylethyl)-6-oxo-5h-indol-5-ylidene)-
3-hydroxy-1-isopropyl-5,6-indolinedione 5-semicarbazone
iprazocromo [inn-spanish]
hydrazinecarboxamide, 2-(3-hydroxy-1-(1-methylethyl)-6-oxo-1,2,3,6-tetrahydro-5h-indol-5-ylidene)-
5,6-indolinedione, 3-hydroxy-1-isopropyl-, 5-semicarbazone
iprazochromum [inn-latin]
2-(1,2,3,6-tetrahydro-3-hydroxy-1-(1-methylethyl)-6-oxo-5h-indol-5-ylidene)hydrazinecarboxamide
nsc-10065
hydrazinecarboxamide,2,3,6-tetrahydro-3-hydroxy-1-(1-methylethyl)-6-oxo-5h-indol-5-ylidene]-
divascan
nsc10065
hydrazinecarboxamide,2,3,5(or 1,2,3,6)-tetrahydro-3-hydroxy-1-(1-methylethyl)-5(or 6)-oxo-6h(or 5h)-indol-6(or 5)-ylidene]-
wln: t56 bn gyvt&j by1&1 dq gunmvz
5, 3-hydroxy-1-isopropyl-, 5-semicarbazone
isopropylnoradrenochrome monosemicarbazone
7248-21-7
novochrome
iprazochrome ,
isopropylnoradenochrome monosemicarbazone
divascan (tn)
iprazochrome (inn)
D07297
CHEBI:135088
EC-000.2092
903a9k181p ,
iprazochromum
unii-903a9k181p
iprazocromo
AKOS015962150
SCHEMBL231514
SCHEMBL231513
iprazochrome [mart.]
iprazochrome [who-dd]
iprazochrom
SCHEMBL10736494
DTXSID70864030
(z)-2-(3-hydroxy-1-isopropyl-6-oxo-2,3-dihydro-1h-indol-5(6h)-ylidene)hydrazinecarboxamide
FT-0773302
DB13541
Q6065428
nsc 10065; novochrome
(3,6-dihydroxy-1-propan-2-yl-2,3-dihydroindol-5-yl)iminourea
CHEMBL4297107

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The dosage was for Divascan 15 mg a day and for pizotifen 3 mg a day."( A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis.
Osterman, PO, 1977
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (71.43)18.7374
1990's4 (28.57)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.60 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (23.53%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (76.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]